Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Deloitte
Healthtrust
Farmers Insurance
Dow
McKesson
Fuji
Teva
Chinese Patent Office
US Department of Justice

Generated: May 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,183,226

« Back to Dashboard

Which drugs does patent 8,183,226 protect, and when does it expire?

Patent 8,183,226 protects LEXISCAN and is included in one NDA.

This patent has twelve patent family members in twelve countries.
Summary for Patent: 8,183,226
Title:Myocardial perfusion imaging method
Abstract: The present disclosure provides 2-adenosine N-pyrazole compounds exemplified by the structure shown below that are potent and selective agonists for A.sub.2A adenosine receptor, compositions comprising these compounds, and methods for using these compounds in a variety of applications including myocardial perfusion imaging and coronary vasodilation methods. ##STR00001##
Inventor(s): Belardinelli; Luiz (Menlo Park, CA)
Assignee: Gilead Sciences, Inc. (Foster City, CA)
Application Number:12/695,096
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 8,183,226

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Astellas LEXISCAN regadenoson SOLUTION;INTRAVENOUS 022161-001 Apr 10, 2008 RX Yes Yes ➤ Sign Up ➤ Sign Up METHOD OF MYOCARDIAL IMAGING ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,183,226

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,470,801 Myocardial perfusion imaging methods and compositions ➤ Sign Up
7,683,037 Myocardial perfusion imaging method ➤ Sign Up
8,906,878 Myocardial perfusion imaging methods and compositions ➤ Sign Up
8,133,879 Myocardial perfusion imaging methods and compositions ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Accenture
Citi
Chinese Patent Office
Cipla
Cantor Fitzgerald
Covington
Dow
McKinsey
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.